Insights on Volume of Distribution of Acids.

J Med Chem

Recursion Pharmaceuticals, Salt Lake City, Utah 84101, United States.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Acidic drugs generally have small steady-state volumes of distribution () around 0.1-0.25 L/kg, due to high binding to serum albumin and low binding to phospholipids in tissues. Acids can reach pharmacological targets in tissues despite small . Enterohepatic recirculation (EHR) of parent drug or reversible acyl glucuronide can increase the of acids. However, rational design to incorporate EHR as a mechanism to increase remains challenging because of the complexity of EHR and lack of reliable predictive tools. Uptake transporters can increase the of acidic drugs by increasing the liver drug concentration and can facilitate EHR through enhancing biliary elimination and glucuronide formation. Half-life extension of acids mainly relies on reducing clearance or using modified release formulations rather than modulating .

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.5c00880DOI Listing

Publication Analysis

Top Keywords

acidic drugs
8
insights volume
4
volume distribution
4
acids
4
distribution acids
4
acids acidic
4
drugs generally
4
generally small
4
small steady-state
4
steady-state volumes
4

Similar Publications

The neuroprotective potential of tyrosine kinase inhibitors (TKIs), potent anticancer drugs, was verified against various neurodegenerative insults, but not Huntington's disease (HD). These promising outcomes were due to their ability to modulate various intracellular signalling pathways. Hence, the current study aimed to evaluate the neuroprotective effects of lapatinib and pazopanib in the 3-nitropropionic (3-NP)-induced HD model in rats.

View Article and Find Full Text PDF

Tight junctions (TJs) are formed where two or three cells meet and are therefore categorized, respectively, into bicellular TJs (bTJs) and tricellular TJs (tTJs). Angubindin-1 is the first tTJ modulator enhancing intestinal macromolecule permeation via binding to the key tTJ proteins, angulin-1 and angulin-3. It is a fragment (amino acids 421-664) derived from domain IV of Clostridium perfringens iota toxin.

View Article and Find Full Text PDF

Breast cancer continues to present a major clinical hurdle, largely attributable to its aggressive metastatic behavior and the suboptimal efficacy of standard chemotherapeutic regimens. Cisplatin (CDDP) is a representative platinum drug in the treatment of breast cancer, however, its therapeutic application is often constrained by systemic toxicity and the frequent onset of chemoresistance. Here, we introduce a novel charge-adaptive nanoprodrug system, referred to as PP@, engineered to respond to tumor-specific conditions.

View Article and Find Full Text PDF

Wounds with extensive tissue damage are highly susceptible for microbial infections delaying the process of wound healing. Currently, biomaterials with therapeutic molecules emerged as key players in wound repairing. This work developed a novel collagen-based hydrogel loaded with allicin and silver nanoparticles.

View Article and Find Full Text PDF

Phosphatidic acid (PA) regulates lipid homeostasis and vesicular trafficking, yet high-affinity tools to study PA in live cells are lacking. We identified the lipin-like sequence of Nir1 (PILS-Nir1) as a candidate PA biosensor based on structural analysis of Nir1's LNS2 domain. Using liposome-binding assays and pharmacological and genetic manipulations in HEK293A cells expressing fluorescent PILS-Nir1, we found that while PILS-Nir1 binds PA and PIP2in vitro, only PA is necessary and sufficient for membrane localization in cells.

View Article and Find Full Text PDF